We are very pleased to welcome Amy Williams to our team. She will assume the position of Director within Iperion – a Deloitte business, from December 6th.
Amy brings 15 years of experience in life sciences, working in Regulatory Affairs – both within the industry and as a software/service provider (Merck Serono, Parexel/Calyx). Amy is passionate about collaborating between industry, health authorities and vendors to alleviate the challenges and needs of the regulatory industry. Her experience in RIMS and belief in the importance of integrating RIMS into the primary process of Regulatory Affairs will be a great contribution to our clients’ journey towards digital transformation.
As one of the industry’s nominated representatives for the inauguration of the EMA Task Force back in 2015, Amy is passionate about the positive changes that IDMP will invoke and the impact that a successful implementation will have on the industry.
The desire to have a direct impact
She brings a very human perspective to her work, too. “My identity as a mum to young children, and the focus this gives me on the health of future generations, has inspired a desire to have a direct impact on the evolution of Regulatory Affairs as a means of getting treatments to patients,” This personal interest has been heightened during the pandemic, too, she added.
“Covid-19 triggered unprecedented change throughout this industry – from accelerated authorizations and rolling reviews for COVID-19 vaccines, and dramatic increases in decentralized clinical trials and remote patient engagement, to the generation of vast quantities of online health data and Real-World Evidence. Now is the time to capitalize on this momentum – to drive the adoption of structured data and standards, and to propel the industry forwards. As we continue to hone the vision for the future of health, I look forward to building on Iperion’s established core competencies and Deloitte’s versatility to support the industry’s next wave of innovation.”
Iperion and Deloitte will benefit enormously from Amy’s Regulatory expertise from industry, her RIM vendor experience, and her broad network of contacts and knowledge base.
Welcoming Amy to the company, Frits Stulp, Deloitte partner and managing director of Iperion, said: “I’m hugely excited that Amy is joining our team, further fueling our drive to be one of the global players in regulatory consultancy, contributing positively and proactively to the future of digital healthcare and bringing a different voice to our market presence. Amy has an enviable track record as a consultant and thought leader in Regulatory Affairs and information management and will be a tremendous asset to our company, and for our clients.”
Director Life Sciences & Healthcare
Iperion – a Deloitte business